Guest Editor(s)

• Prof. Chiara Riganti, MD

  Associate professor of biochemistry, Oncological Pharmacology Lab, Department of Oncology, University of Torino, via Santena 5/bis, Torino, Italy.

  Website | E-mail

• Prof. Joanna Kopecka, PhD

  Assistant professor of biochemistry, Oncological Pharmacology Lab, Department of Oncology, University of Torino, Torino, Italy.

  Website | E-mail

Special Issue Introduction

Despite the recent improvements in our knowledge on glioblastoma genotype and the enlarged spectrum of drugs and drug delivery-technologies developed for glioblastoma, the overall survival of patients with this tumor has not improved in the last years. Chemoresistance can be due to tumor intrinsic factors, mainly related to specific alterations in genotypic, epigenetic and miRNOME profile, or to extrinsic factors, such as the presence of blood-brain barrier and hypoxic niches, which favor the growth of chemoresistant stem cells. Identifying new biomarkers that stratify patients in responders or non-responders to pharmacological therapies, and finding innovative strategies improving drug delivery and drug efficacy, are two unmet needs in the current approach to the diagnosis and treatment of this tumor. This special issue will provide an overview of the latest discoveries in terms of biomarkers identification, chemoresistance mechanisms, and chemosensitizing strategies for glioblastoma.

Keywords

Glioblastoma, chemoresistance, glioblastoma stem cells, blood-brain barrier, ABC transporters, miRNAs, tyrosine kinase receptors inhibitors, anti-angiogenic drugs, convection-enhanced delivery, nanocarriers

Submission Deadline

30 Sep 2020

Submission Information

For Author Instructions, please refer to http://cdrjournal.com/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr&SpecialIssueId=352
Submission Deadline: 30 Sep 2020
Contacts: Belinda Zhang, Assistant Editor, belinda@cdrjournal.com
Bill Li, Managing Editor, bill@cdrjournal.com